Drug-Eluting Stents Could Experience Blockage From New Safety Data
This article was originally published in The Gray Sheet
Executive Summary
Public questions concerning the safety of the Taxus andCypher drug-eluting stents increased measurably last week amid results reported at a major cardiology conference and a disclosure by Boston Scientific that Taxus is associated with an increased risk of blood clots
You may also be interested in...
Drug-Eluting-Stent Market Penetration At Nadir? Rebound Forecast At TCT
U.S. drug-eluting-stent market penetration reached an all-time low in September, but clinicians meeting last week in Washington, D.C., are confident new data will help to reverse the trend that began just over a year ago
Drug-Eluting-Stent Market Penetration At Nadir? Rebound Forecast At TCT
U.S. drug-eluting-stent market penetration reached an all-time low in September, but clinicians meeting last week in Washington, D.C., are confident new data will help to reverse the trend that began just over a year ago
Vienna Meeting Goes Relatively Smoothly For Drug-Eluting Stent Makers
Drug-eluting stent manufacturers did not have to answer to any surprise negative results at the European Society of Cardiology conference in Vienna this year and, in fact, got some good news from an ongoing registry